NCT05621499View on ClinicalTrials.gov

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

HAIC

Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles

DRUG

Sintilimab

200mg，iv，d1，q3w，a total of 3 cycles

DRUG

Lenvatinib

12 or 8mg/kg，po，qd，a total of 3 cycles

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT05621499 - HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter